BIO-CHEM(SH:603360)2018-08-28 16:00Financial Performance - The company's operating revenue for the first half of 2018 was ¥252,056,841.71, representing a 31.96% increase compared to ¥191,015,251.35 in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2018 was ¥63,086,840.98, up 15.53% from ¥54,607,121.92 in the previous year[16]. - The net cash flow from operating activities increased by 30.01%, reaching ¥73,447,130.06 compared to ¥56,492,478.96 in the same period last year[16]. - The company reported a net profit after deducting non-recurring gains and losses of ¥61,207,392.73, which is an 18.92% increase from ¥51,467,381.41 in the previous year[16]. - Basic earnings per share for the first half of 2018 were ¥0.34, a 17.24% increase from ¥0.29 in the same period last year[17]. - The company achieved a revenue of CNY 252.06 million, representing a year-on-year growth of 31.96%[34]. - The net profit attributable to shareholders was CNY 63.09 million, an increase of 15.53% compared to the previous year[29]. - The company reported a total profit for the current period of ¥75,995,151.83, compared to ¥64,399,800.51 in the previous period, marking an 18.5% increase[99]. - The company’s total comprehensive income for the current period was ¥62,931,421.39, compared to ¥54,592,620.93 in the previous period, reflecting an increase of 15.5%[99]. Assets and Liabilities - The company's total assets as of the end of the reporting period were ¥849,692,618.89, a 9.03% increase from ¥779,330,217.36 at the end of the previous year[16]. - Total liabilities amounted to CNY 100,339,712.58, up from CNY 92,908,732.45, which is an increase of around 8.5%[93]. - Owner's equity reached CNY 749,352,906.31, compared to CNY 686,421,484.91, showing a growth of about 9.2%[93]. - Cash and cash equivalents increased to CNY 222,077,606.84 from CNY 134,245,173.62, marking a significant rise of approximately 65.4%[91]. - Accounts receivable decreased to CNY 88,890,284.97 from CNY 99,832,727.64, a decline of about 11%[91]. - Inventory increased to CNY 49,505,854.01 from CNY 47,589,573.63, reflecting a growth of approximately 4%[91]. Production and Operations - The production capacity of the company's isothiazolinone-based biocides exceeded 10,000 tons, with plans to surpass 20,000 tons after future projects are completed[25]. - The company is actively advancing projects to increase production capacity for CIT/MIT and BIT series products, aiming for completion by the end of 2018[32]. - The company has maintained stable production without interruptions due to environmental issues, indicating effective operational management[29]. Research and Development - The company has a strong focus on R&D, with expenditures amounting to CNY 3.30 million, a 6.30% increase from the previous year[34]. Environmental Compliance - The company has established a complete environmental management system, conducting annual monitoring of wastewater and air emissions, with real-time data transmission to the environmental protection bureau[68]. - The company’s environmental protection measures are in compliance with the relevant standards, ensuring all emissions are within permissible limits[58]. - The company reported a continuous operation of wastewater treatment facilities with a design capacity of 800 tons/day since 2011[60]. - The company has implemented air pollution control facilities with a design capacity of 2500 cubic meters/hour, operational since 2011[60]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 11,111[78]. - The top ten shareholders held a total of 133,333,334 shares, representing 100% of the total shares[80]. - Dalian Sanxin Investment Co., Ltd. and Dalian Tongyun Investment Co., Ltd. each held 38,666,667 shares, accounting for 29% of the total shares[80]. Risks and Challenges - The company faces risks from intensified domestic market competition, potential leakage of core technology, and environmental protection regulations[42][43]. Corporate Governance - The company experienced a change in its board of directors, with several new appointments made during the reporting period[87]. - The company reported no changes in the controlling shareholder or actual controller during the reporting period[86]. Accounting Policies - The accounting policies and estimates are in accordance with relevant enterprise accounting standards, particularly regarding revenue recognition[122]. - The company does not recognize changes in the fair value of equity instruments in profit or loss[154].